Mainstay Medical Announces Participation at the American Association of Neurological Surgeons (AANS) Annual Meeting
Retrieved on:
Monday, August 23, 2021
General Health, Health, Medical Devices, Shift, People, Industry, Principal investigator, Terminology, European Economic Area, Quality of life, Pain, Clinical trial, Department, Nature, L3, Anxiety, American Association of Neurological Surgeons, Harvard Medical School, Muscle, Disability, AANS, Sleep, Assistant, Division, Time, American Association, Spine, Congress of Neurological Surgeons, Forward-looking statement, Uncertainty, Foreskin restoration, Risk, Goal, Patient, Depression, CEO, Work, Hospital, Regulation of therapeutic goods, Association, FDA, Paradigm shift, Nervous system, Dentistry, Medical device, Risk management, Mainstay Medical, ReActiv8®, Chronic Low Back Pain, MAINSTAY MEDICAL, REACTIV8®, CHRONIC LOW BACK PAIN
Mainstay Medical Holdings plc today announced its participation in the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, to be hosted virtually on August 21-25, 2021.
Key Points:
- Mainstay Medical Holdings plc today announced its participation in the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, to be hosted virtually on August 21-25, 2021.
- Mainstay Medicals participation will focus on ReActiv8, its implantable Restorative Neurostimulation system to treat intractable chronic low back pain.
- We are excited to introduce ReActiv8 to the AANS membership, said Jason Hannon, CEO of Mainstay Medical.
- Mainstay Medical is headquartered in Dublin, Ireland and has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.